Everything below concerns hGH fragment. We keep the language plain, cite what the science says, and separate well-supported claims from open questions.
Last reviewed on 2026-01-20. Where a claim depends on a specific study, the study is described rather than over-claimed.
AOD-9604 is a synthetic peptide modeled on the C-terminal region of human growth hormone. It corresponds to residues 176-191 of the 191-amino-acid hGH sequence. The fragment is not the full hormone and lacks the receptor-binding region associated with growth and metabolic effects of hGH. Researchers developed it to isolate a specific portion of hGH for study. Its exact sequence and length are often stated in peptide catalogs and patents.
The peptide is frequently described as a growth hormone fragment, although it is chemically distinct from full-length hGH. AOD-9604 contains 16 amino acids and includes two cysteine residues that can form an intramolecular disulfide bond. In solution, this structural feature can influence folding, aggregation, and stability. Published descriptions sometimes call it hGH 176-191 or AOD9604, with spacing and capitalization varying. Such naming differences can complicate literature searches, database entries, and product verification.
Researchers have studied the fragment in cell and animal models to understand its metabolic actions. Some experiments report effects on fat breakdown and fat storage pathways, but the underlying mechanism remains incompletely defined. AOD-9604 does not appear to stimulate the same broad growth hormone receptor signaling as full-length hGH. Whether its observed activities arise from direct receptor interactions or downstream metabolic changes is an open question. Results from different assays are not always consistent.
AOD-9604 is a synthetic peptide whose structure corresponds to a C-terminal segment of human growth hormone. It is often described as hGH fragment 176-191, a 16-amino-acid sequence. The peptide was designed to isolate a region of hGH associated with fat metabolism while avoiding the full hormone's growth-promoting actions. Laboratory and commercial materials typically present it as a lyophilized powder for research use. Its identity is defined by amino acid sequence, not by a single brand.
The fragment includes residues that can form an internal disulfide bond between two cysteine positions. This structural feature can influence how the peptide folds and how stable it is in solution. AOD-9604 differs from full-length hGH in size and receptor interactions; it does not contain the entire growth hormone sequence. Published descriptions sometimes use slightly different residue numbering, so sequence information should be checked against primary sources. The molecule is small compared with intact hGH, which affects analytical detection and purification approaches.
| Property | Value | Notes |
|---|---|---|
| Molecular class | Synthetic peptide | Derived from a fragment of human growth hormone |
| Sequence basis | hGH residues 176-191 | Commonly described as a 16-amino-acid fragment |
| Appearance | White to off-white powder | Typical for lyophilized research peptides |
| Solubility | Soluble in water or aqueous buffer | Exact solubility depends on pH and purity |
| Common synonyms | AOD9604; hGH 176-191 | Spelling and punctuation vary across sources |
The compound has been studied as a potential treatment for obesity and related metabolic conditions. Published trials have examined changes in body weight, fat mass, and safety markers over limited durations. Results have been mixed or modest, and no large-scale outcome trials are established. Regulatory agencies in several countries have not approved it as a therapeutic drug. Some commercial products have been marketed outside regulated pharmaceutical channels, which raises questions about quality and claims.
In the scientific literature, AOD-9604 appears in reviews of growth hormone fragments and in discussions of peptide-based metabolic research. Some sources distinguish it from growth hormone itself, while others group it with compounds marketed for weight management. The evidence base is small compared with approved obesity medications. Questions about long-term efficacy and clinical relevance remain open, and independent replication of key findings is limited. Most published reports are early-stage and exploratory.
AOD-9604 is listed as a prohibited substance in sport by the World Anti-Doping Agency. It falls under the peptide hormones, growth factors, related substances, and mimetics class on the prohibited list. Anti-doping organizations treat its presence in an athlete's sample as an adverse finding unless a therapeutic use exemption applies. The prohibition reflects concerns about performance enhancement in competitive settings and the difficulty of distinguishing exogenous peptide use from endogenous hormone fragments.
Detection of AOD-9604 in biological samples relies on analytical techniques capable of distinguishing a small synthetic peptide from related endogenous sequences. Liquid chromatography coupled with tandem mass spectrometry is commonly used for confirmatory analysis. Sample preparation may involve immunoaffinity enrichment or solid-phase extraction to concentrate the peptide. Because the molecule is small and may be present at low concentrations, assay sensitivity and specificity are ongoing analytical challenges. Laboratories also validate methods against reference materials when available.
Regulatory interest in AOD-9604 increased after high-profile anti-doping cases involving peptide products. In some cases, the substance was supplied under alternative names or in compounded preparations, complicating traceability. Sports tribunals and anti-doping panels have discussed whether the peptide was explicitly banned at the time of use, leading to clarifications by the World Anti-Doping Agency. For consumers and researchers, the legal status can vary by jurisdiction, and products marketed as research chemicals may lack independent quality verification.
Laboratory studies have reported that AOD9604 can increase lipolysis and reduce lipid accumulation in fat cells. The precise molecular target remains uncertain, and the compound does not appear to activate the growth hormone receptor in the same way as full-length hGH. Proposed mechanisms include effects on beta-adrenergic signaling and enzymes involved in fatty acid synthesis, but these pathways are not firmly established. Because most evidence comes from cell and animal models, whether the same effects occur in humans is an open question.
Clinical development of AOD9604 included trials in people with obesity, but the results did not lead to approval as a prescription medicine in major markets. Interest later shifted to research settings and to unapproved products marketed for body composition. Regulatory agencies have questioned whether the peptide qualifies as a dietary ingredient, and some have issued warnings about its presence in supplements. Long-term human safety data are limited, and questions about efficacy, dosing, and target populations remain unresolved.
AOD9604 is a synthetic peptide modeled on the C-terminal region of human growth hormone. It corresponds to a short sequence near the end of the 191-amino-acid hormone, often described as residues 176–191 or a related fragment. Researchers designed it to separate metabolic effects from the growth-promoting actions of full-length growth hormone. Early work in the 1990s explored it as a candidate for weight and lipid disorders. It is not a naturally circulating hormone fragment produced in large amounts.
=== Musculoskeletal symptoms === Joint instability and soft tissue injuries: Dislocations, subluxations, or damage to muscles, ligaments, tendons, synovium, or cartilage as a result of excessive joint movement. Chronic pain: Recurrent joint pain that can develop into hyperalgesia, with a higher rate of small fiber neuropathy in some individuals. Disturbed proprioception: Reduced proprioception and muscle weakness, creating a cycle of increasing activity limitations
== Pre-trial proceedings == The first evidence that the prosecution introduced against Agüero, was immediately after her arrest, alleging that Agüero was behind every case, both deaths and decompensations, and that Agüero herself was in the place of the incidents, further alleging that she was the one who notified the doctors and other medical personnel that an emergency with a newborn was underway. On the same day that the prosecution introduced their first accusation, the court in charge of the pre-trial procedures, ordered psychiatric and psychological evaluations of Agüero, to later dictate pre-trial detention. In January 2023, the psychiatric evaluators determined that Agüero knows right from wrong and that she does not suffer from any mental disorder. The psychiatrists further argued that Agüero tried to "manipulate the interview" and that she has difficulties in regards to feeling what others do. After the evaluation, Agüero's indictment was confirmed. The prosecution alleged that in November 2021, Agüero searched on Google "how to dose potassium and insulin injections in newborns." Agüero denied that she searched "how to apply potassium injections" on Google and alleged that she does not have the knowledge to perform such a procedure. Another accusation argued that Agüero concealed the syringes with which she allegedly injected the babies with potassium, under her sleeves, with other medical personnel noting that she went to work with long-sleeved shirts even on hot summer days.
Campbell-Bannerman tried to keep these forces together at the head of a moderate Liberal rump, but in 1901 he delivered a speech on the government's "methods of barbarism" in South Africa that pulled him further to the left and nearly tore the party in two. The party was saved after Salisbury's retirement in 1902 when his successor, Arthur Balfour, pushed a series of unpopular initiatives such as the Education Act 1902 and Joseph Chamberlain called for a new system of protectionist tariffs. Campbell-Bannerman was able to rally the party around the traditional liberal platform of free trade and land reform and led them to the greatest election victory in their history. This would prove the last time the Liberals won a majority in their own right. Although he presided over a large majority, Sir Henry Campbell-Bannerman was overshadowed by his ministers, most notably H. H. Asquith at the Exchequer, Edward Grey at the Foreign Office, Richard Burdon Haldane at the War Office and David Lloyd George at the Board of Trade. Campbell-Bannerman retired in 1908 and died soon after. He was succeeded by Asquith, who stepped up the government's radicalism. Lloyd George succeeded Asquith at the Exchequer and was in turn succeeded at the Board of Trade by Winston Churchill, a recent defector from the Conservatives.
Sources: en.wikipedia.org
=== Helium charged vacuum test === In this test method, the part is pressurized with helium, or a helium and hydrogen mixture to reduce cost, while sitting in a vacuum chamber. The vacuum chamber is connected to a vacuum pumping system and a leak detector. Once the vacuum has reached the leak detector operating pressure, any helium leakage will be measured. Sometimes after leak testing concludes, a burst test, i.e. at 40 bar may be conducted in the same chamber. This test method may be optimal for certain components: airbag canisters, evaporators, condensers, high-voltage filled SF6 switchgear, as pressures during testing may simulate those seen in component application, along with positioning any seals, gaskets, etc. into their operating position during testing.
== History == Chlorprothixene was the first of the thioxanthene antipsychotics to be synthesized. It was introduced in 1959 by Lundbeck. Lometraline, tametraline, and sertraline were reportedly derived via structural modification of chlorprothixene.
Action Game – Grand Theft Auto: Vice City Adventure Game – The Legend of Zelda: The Wind Waker Animation or Intro – Soulcalibur II (Jame Chung Edition) Children's Game – EyeToy: Play Design – Grand Theft Auto: Vice City Game Boy Advance Game – Advance Wars 2: Black Hole Rising Game on Any Platform – The Year's Best Game – Call of Duty GameCube – Metroid Prime Mobile Game – Tony Hawk's Pro Skater Multiplayer – Battlefield 1942 Original Music – Harry Potter and the Chamber of Secrets PC – Grand Theft Auto: Vice City PS2 – Grand Theft Auto: Vice City Racing – Project Gotham Racing 2 Sound – Grand Theft Auto: Vice City Sports – FIFA Football 2004 Strategy – Advance Wars 2: Black Hole Rising Sunday Times Reader Award for Games – Grand Theft Auto: Vice City Technical Achievement – EyeToy: Play Xbox – Star Wars: Knights of the Old Republic Special Award (Games) – Chris Deering
Adnexal mass entry in the public domain NCI Dictionary of Cancer Terms Emedicine overview This article incorporates public domain material from Dictionary of Cancer Terms. U.S. National Cancer Institute.
Sources: en.wikipedia.org
The Cuban Freemasons started shouting "Hold my Cuba Libra!" Filema Duarte's decision was later supported by the Cuban Ministry of Justice and the Communist Party. Also supporting Filema Duarte's decision were Grand Secretary Juliannys Galano, Grand Treasurer Juan Carlos Yero, and the President of the Supreme Court of Masonic Justice, Rancel Montero. After the suspended meeting, pressure mounted on the office of the Grand Master. Filema Duarte announced another session of the Grand Lodge would occur in May. However, he canceled this meeting after receiving what he called threats against his person. Government agents from the Office of Associations then interrogated members who had called for the Grand Master's removal. These interrogations did not concern Filema Duarte; the government was attempting to gather evidence for a case on Grand Commander Viñas Alonso. The Office of Associations informed these Freemasons that Viñas Alonso was occupying the office of Grand Commander illegally, and that they had to elect a new Grand Commander. One Cuban Freemason later told journalists: "It is the plinth of cynicism, Viñas Alonso isn't the problem! We need to get rid of Filema Duarte! Filema Duarte is a stone in his shoes."
===== Supplemental Offer and Acceptance Program ===== The Supplemental Offer and Acceptance Program (SOAP) is a process for partially matched and fully unmatched applicant through the Match. Previous to the creation of SOAP, applicants were given the opportunity to contact the programs about the open positions in a process informally called "the scramble". This frantic, loosely structured system forced soon-to-be medical school graduates to choose within minutes programs not on their original Match list. In 2012, the NRMP introduced the organized system called SOAP. As part of the transition, Match Day was also moved from the third Thursday in March to the third Friday. The SOAP occurs during Match Week. First the applicants eligible for SOAP, are informed they did not secure a Match position on the Monday of Match Week. The locations of remaining unfilled residency positions are released to the unmatched applicants the following day. Then programs contact applicants for interviews that usually occur via phone calls. After that, programs prepare lists of applicants and the positions open are offered by each program one at a time to the top applicant on their list. The applicant may accept the offer or reject it. If the offer is rejected it will go to the next applicant in the program list during the next round of SOAP. During Match year 2021 there were four rounds of SOAP.
==== Nomenclature ==== Papers published prior to a recent community consensus employ differing sets of nomenclature. The precursor peptide has been referred to previously as prepeptide, prepropeptide, or structural peptide. The leader peptide has been referred to as a propeptide, pro-region, or intervening region. Historical alternate terms for core peptide included propeptide, structural peptide, and toxin region (for conopeptides, specifically).
Sources: en.wikipedia.org
No, it is a synthetic peptide fragment corresponding to a small portion of hGH. It is not the full 191-amino-acid hormone and does not reproduce all of hGH's effects.
It is commonly described as a 16-amino-acid peptide based on residues 176-191 of human growth hormone. Some sources vary in notation, so checking the stated sequence is useful.
It is not typically described as a standalone natural hormone. The sequence is derived from the C-terminal region of human growth hormone, but the synthetic peptide is a laboratory-made construct.
It is a synthetic peptide based on a C-terminal fragment of human growth hormone. It is commonly referred to as hGH fragment 176-191 and is studied for metabolic effects rather than growth effects.